Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6659757 | 0.86 | MAOB (0.47) | CASRAOC3SMN1; SMN2ACHEL3MBTL1 | |
| SCHEMBL6793398 | 0.86 | MTNR1A (0.53) | CASRMTNR1AMTNR1BAOC3L3MBTL1 | |
| SCHEMBL12003070 | 0.86 | AOC3 (0.42) | CASRMTNR1AMTNR1BAOC3SMN1; SMN2 | |
| SCHEMBL8317373 | 0.82 | CASR (0.51) | CASRCA4MTNR1AMTNR1BAOC3 | |
| SCHEMBL874908 | 0.82 | ACP3 (0.56) | CA4L3MBTL1CA1CA2CA7 | |
| SCHEMBL5263393 | 0.82 | AOC3 (0.50) | CASRAOC3ACHEL3MBTL1CHRM2 | |
| SCHEMBL12564464 | 0.81 | NPC1 (0.49) | MTNR1AMTNR1BSMN1; SMN2L3MBTL1CHRM2 | |
| SCHEMBL1050770 | 0.80 | CASR (0.54) | CASRCA4MTNR1AMTNR1BAOC3 | |
| Benzene SCHEMBL11146992 | 0.80 | CASR (0.54) | CASRCA4MTNR1AMTNR1BAOC3 | |
| SCHEMBL1588867 | 0.80 | CASR (0.50) | CASRAOC3SMN1; SMN2ACHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121594-B1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8592453-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-8378121-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110020231-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021787-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7834185-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2121594-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| WO-2008103426-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM5, CHRM1 | CASR 297/4885CA4 1400/4885MTNR1A 184/4885 |
| US-20110021787-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | CASR 297/4885CA4 1400/4885MTNR1A 184/4885 |
| US-20110020231-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | CASR 297/4885CA4 1400/4885MTNR1A 184/4885 |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | CASR 297/4885CA4 1400/4885MTNR1A 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.